Compositions comprising circular polyribonucleotides for protein modulation and uses thereof

Inventors

Kahvejian, Avak • Plugis, Nicholas McCartney • DE BOER, Alexandra Sophie

Assignees

Vl50 Inc • Flagship Pioneering Inc • Flagship Pioneering Innovations VI Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12636369-B2

Patent

Publication Date

2026-05-26

Expiration Date


Abstract

This invention relates to compositions comprising circular polyribonucleotides and uses thereof.

Core Innovation

The invention describes a complex comprising a circular polyribonucleotide bound to two or more copies of a target protein and two or more copies of a substrate protein. The target protein is a ubiquitin ligase that modulates the substrate protein, thereby promoting degradation of the substrate protein. The circular polyribonucleotide brings the target protein and substrate protein into proximity to promote substrate modification, ubiquitination, and degradation.

The scaffold recruits proteins through RNA binding sites, conjugated small-molecule ligands, or combinations thereof, including modified nucleotides and click-chemistry-compatible conjugation moieties. Disclosed arrangements encompass a thalidomide-conjugated circular polyribonucleotide that binds Cereblon, JQ1 conjugates targeting BRD4, and bifunctional designs targeting proteins such as EGFR for proteasomal or lysosomal degradation. Reported findings include reduced BRD4 levels and cancer-cell viability, as well as motif-dependent HuR binding.

Claims Coverage

The claims identify one independent claim and several dependent claims, encompassing five inventive features directed to a degradation-inducing scaffold complex and associated compositions.

Circular polyribonucleotide complex promoting substrate degradation

A complex comprising a circular polyribonucleotide bound to two or more copies of a target protein and to two or more copies of a substrate protein, wherein the target protein is a ubiquitin ligase that modulates the substrate protein to promote degradation of the substrate protein.

Multiple target-protein binding arrangements

The circular polyribonucleotide binds to five or more copies of the target protein, or connects through two or more binding moieties that each bind the target protein.

Conjugated modified-nucleoside binding arrangements

Modified nucleosides are conjugated to compounds that bind the substrate protein and the target protein, connecting both proteins to the circular polyribonucleotide.

Specified ubiquitin-ligase classes

The E3 ubiquitin ligase is selected from a HECT, RING-finger, U-box, or PHD-finger ubiquitin ligase.

Pharmaceutical composition comprising the complex

A pharmaceutical composition comprising the circular polyribonucleotide complex.

The claims center on a circular polyribonucleotide complex binding multiple copies of a ubiquitin ligase and substrate protein to promote degradation, further defining binding arrangements, ligase classes, and pharmaceutical compositions.

Stated Advantages

Circular RNA is stated to offer increased stability and half-life relative to linear RNA.

Documented Applications

Promotion of substrate ubiquitination and degradation by bringing a ubiquitin ligase and substrate protein into proximity using the circular polyribonucleotide scaffold, including recruiting and degrading BRD4 to reduce BRD4 levels and cancer-cell viability.

Conjugates comprising thalidomide and JQ1 targeting CRBN and BRD4.

Proposed bifunctional designs targeting proteins such as EGFR, alongside possible therapeutic applications.

Selective protein binding, protein sequestration, and altered translation, including motif-dependent HuR binding to circular RNA.

A pharmaceutical composition comprising the complex.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.